In 25 people with Graves' disease who were still hyperthyroid despite medication, weekly injections of batoclimab led to a rapid drop in thyroid hormone levels, and by 12 weeks, nearly four out of five had hormone levels return to normal without needing higher doses of their existing thyroid drugs.
Claim Context
In 25 adults with treatment-resistant Graves' disease, weekly subcutaneous administration of batoclimab (680 mg for 12 weeks, then 340 mg for 12 weeks) was associated with a mean reduction of 5.5 pmol/L in free triiodothyronine and 7.7 pmol/L in free thyroxine within one week, with 76% of patients achieving normal thyroid hormone levels by week 12 without increasing anti-thyroid drug doses.
“As early as Week 1 (after a single dose of batoclimab), marked reductions from baseline in serum FT3 (mean [SD] change, -5.5 [4.9] pmol/l), FT4 (mean [SD] change,-7.7 [6.8] pmol/L)... By Week 2, 15/25 (60%) patients achieved FT3 and FT4 levels ≤ULN without an increase in ATD dose; this increased to 19/25 (76%) patients at Week 12, including 14/25 (56%) who were off ATD.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether batoclimab consistently reduces thyroid hormone levels and induces euthyroidism across multiple randomized controlled trials in Graves' disease, accounting for heterogeneity in dosing, patient characteristics, and outcome measures.
A systematic review and meta-analysis of all published randomized, double-blind, placebo-controlled trials of batoclimab in Graves' disease, including at least 500 participants across multiple centers, with standardized dosing (680 mg then 340 mg weekly), primary outcomes of FT3/FT4 normalization at 12 and 24 weeks, and secondary outcomes of TRAb reduction and ATD discontinuation rates.
Whether batoclimab causes a greater reduction in thyroid hormone levels compared to placebo or standard care in patients with Graves' disease, independent of confounding factors.
A double-blind, placebo-controlled, multicenter trial of 150 adults with confirmed Graves' disease and persistent hyperthyroidism despite ATD, randomized 1:1 to receive weekly subcutaneous batoclimab (680 mg then 340 mg) or saline placebo for 24 weeks, with primary endpoint being proportion achieving FT3 and FT4 ≤ULN at week 12 without ATD dose increase, and secondary endpoints including TRAb reduction, TSH normalization, and ThyPRO-39 scores.
Whether batoclimab use in real-world clinical practice is associated with sustained normalization of thyroid function and reduced need for anti-thyroid drugs over 1–2 years.
A prospective cohort study following 300 adults with Graves' disease treated with batoclimab in routine clinical care across multiple centers, measuring FT3, FT4, TRAb, TSH, ATD dose, and relapse rates at 6, 12, 18, and 24 months, with adjustment for baseline severity, age, and concomitant therapies.
Whether patients who achieve sustained euthyroidism after batoclimab differ in baseline characteristics (e.g., TRAb titer, duration of disease) from those who do not.
A case-control study comparing 50 Graves' disease patients who achieved and maintained euthyroidism for ≥12 months after batoclimab to 50 matched controls who did not, assessing baseline TRAb levels, thyroid volume, and ATD history as predictive factors.
The prevalence of normal thyroid function among patients currently receiving batoclimab in clinical practice.
A cross-sectional survey of 500 patients with Graves' disease currently on batoclimab across multiple clinics, measuring FT3, FT4, TSH, and ATD status at a single time point to estimate the proportion achieving euthyroidism.